The market is primarily driven by the increasing adoption of pneumococcal conjugate vaccines (PCVs) and pneumococcal polysaccharide vaccines (PPSVs). Continuous advancements in vaccine formulations and the introduction of higher-valent vaccines are further strengthening market growth. The rising focus on preventive healthcare and immunization awareness campaigns is also fueling demand globally. In addition, global initiatives aimed at increasing vaccine coverage in low- and middle-income countries are contributing significantly to market expansion. Organizations supporting vaccination programs are playing a key role in improving accessibility and affordability.
The global pneumococcal vaccines market size in 2026 is witnessing steady growth driven by rising awareness about immunization, increasing prevalence of pneumococcal diseases, and expanding vaccination programs worldwide. According to Fortune Business Insights, the global pneumococcal vaccines market size was valued at USD 8.8 billion in 2025. The market is projected to grow from USD 9.15 billion in 2026 to USD 14.76 billion by 2034, exhibiting a CAGR of 6.17% during the forecast period. North America dominated the pneumococcal vaccines market with a market share of 29.20% in 2025.
Pneumococcal vaccines play a crucial role in preventing infections caused by Streptococcus pneumoniae, including pneumonia, meningitis, and bacteremia. Governments and healthcare organizations are increasingly focusing on immunization programs to reduce disease burden, particularly among children and the elderly population.
𝗧𝗼𝗽 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗜𝗻 𝗧𝗵𝗲
GSK plc. (U.K.)
Merck & Co., Inc. (U.S.)
Abbott (U.S.)
Sanofi (France)
Pfizer (U.S.)
Inventprise (U.S.)
Vaxcyte (U.S.)
Walvax Biotechnology Co., Ltd. (China)
SK Bioscience (South Korea)
𝗠𝗮𝗿𝗸𝗲𝘁 𝗗𝗿𝗶𝘃𝗲𝗿𝘀 & 𝗥𝗲𝘀𝘁𝗿𝗮𝗶𝗻𝘁𝘀:
Market Drivers: The increasing prevalence of pneumococcal infections worldwide is one of the key factors driving market growth. The growing geriatric population, which is more susceptible to infections, further boosts the demand for vaccines. Additionally, government-supported immunization programs and favorable reimbursement policies are encouraging vaccine adoption.
Technological advancements in vaccine development, including the introduction of higher-valency pneumococcal conjugate vaccines, are improving efficacy and coverage. Increased healthcare spending and rising awareness about preventive care are also contributing to the expansion of the market.
Market Restraints: Despite positive growth prospects, the market faces certain challenges such as high costs associated with vaccine development and distribution. Limited access to vaccines in underdeveloped regions and logistical challenges related to cold chain storage also hinder market growth. Additionally, vaccine hesitancy in certain populations may impact adoption rates.
𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲:
The pneumococcal vaccines market report provides a comprehensive analysis of key market trends, growth drivers, restraints, and opportunities. It includes detailed insights into market size, share, and forecast, along with an in-depth evaluation of competitive dynamics. The report also highlights recent developments, technological advancements, and strategic initiatives undertaken by key players.
Furthermore, the report offers segmentation analysis based on vaccine type, distribution channel, and region. It provides valuable insights for stakeholders, investors, and industry participants to make informed business decisions.
𝗠𝗮𝗿𝗸𝗲𝘁 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲:
The competitive landscape of the pneumococcal vaccines market is characterized by the presence of established pharmaceutical companies and emerging biotech firms. Leading players are focusing on research and development activities to introduce innovative vaccine solutions and expand their product portfolios.
Strategic collaborations, mergers, and acquisitions are commonly observed strategies to strengthen market position. Companies are also investing in expanding their manufacturing capacities and global distribution networks to meet the increasing demand for vaccines.
𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝘀:
The pneumococcal vaccines market is segmented based on vaccine type, target population, and distribution channel.
By Product Type (PCV13, PCV15, PCV20, PCV21, PPSV23, and Others)
By Age Group (Pediatric and Adults)
By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others)
Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/pneumococcal-vaccines-market-113672
𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀:
North America holds the largest share of the pneumococcal vaccines market, driven by well-established healthcare infrastructure, high vaccination coverage, and strong government support. The presence of major pharmaceutical companies further strengthens the regional market.
Europe also represents a significant market share due to increasing immunization programs and awareness campaigns. Asia Pacific is expected to witness substantial growth during the forecast period, owing to a large population base, rising healthcare investments, and expanding vaccination initiatives.
Emerging economies in Latin America and the Middle East & Africa are gradually improving their vaccination coverage through government efforts and international support, contributing to overall market growth.
𝗙𝘂𝘁𝘂𝗿𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗰𝗼𝗽𝗲:
The future of the pneumococcal vaccines market looks promising, with continuous advancements in vaccine technology and increasing focus on disease prevention. The development of next-generation vaccines with broader serotype coverage is expected to create new growth opportunities.
Additionally, the expansion of immunization programs in developing countries and the integration of vaccines into national healthcare systems will further drive market growth. Increased collaboration between governments, healthcare organizations, and pharmaceutical companies is likely to enhance vaccine accessibility and affordability.
The growing emphasis on public health and preventive care is expected to sustain the demand for pneumococcal vaccines over the forecast period.
Recent Industry Developments
June 2025: SK Bioscience, a biotech company, expanded its L HOUSE production facility in Andong to support the global supply of its 21-valent Pneumococcal Conjugate Vaccine (PCV) candidate, GBP410. The facility received official building use approval from the City of Andong.
October 2024: Chad became the first Gavi-supported country to launch routine pneumococcal disease, malaria, and rotavirus immunizations.
Conclusion
The pneumococcal vaccines market is set for steady growth driven by rising awareness, increasing disease burden, and expanding immunization programs. With strong support from governments and healthcare organizations, along with continuous innovation by key market players, the industry is expected to witness significant advancements in the coming years.
The focus on preventive healthcare and global vaccination initiatives will continue to play a crucial role in shaping the future of the pneumococcal vaccines market.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Top comments (0)